🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Effects of Autogenic Inhibition Versus Reciprocal Inhibition in Individuals With Lower Cross Syndrome

RecruitingNAAges 25 Years - 50 YearsAllFoundation University Islamabad
NCT07526051 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study examines the effects of autogenic inhibition (PFS) versus reciprocal inhibition in individuals with lower cross syndrome

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Both Males and Females will be included in our study Age 25-50 years Four positive screening tests (Thomas Test, Abdominal Strength Test, Glutues Maximus Test, Ely's Test) chronic Pain in lower Back Region (\>3 on VAS) lasting for more than 2 months Exclusion Criteria: * Osteoporosis Congenital Hip Dysplasia History of Fracture History of Inflammatory Arthritis Pregnancy
💊

What it tests

  • Autogenic Inhibition (PFS) Group A
  • Reciprocal Inhibition Group B
📍

Where

1 site
Foundation University College of Physical Therapy
Islamabad, Pakistan
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy